Results 181 to 190 of about 18,647 (241)

Bullous Pemphigoid Following IgG/IgA Pemphigus: Possible Involvement of SGLT2 and DPP-4 Inhibitors. [PDF]

Acta Derm Venereol
Ikeda A, Tani N, Ishii N, Koga H, Yoshida Y.   +4 more
europepmc   +1 more source

Desquamative Gingivitis: A Narrative Review of Practical Diagnostic Approach for General Dental Practitioners. [PDF]

Cureus
Anitha K, Shanthi V, Ebenezer M, Harshini G, Maheswaran T, Ilayaraja V.   +5 more
europepmc   +1 more source

Azathioprine-Induced Hypersensitivity Syndrome Presenting as Sepsis-Like Syndrome in a Patient With Mucous Membrane Pemphigoid: A Report of a Rare Case. [PDF]

Cureus
Usman M, Murtaza L, Basit A, Khan MZ, Asif MZ.   +4 more
europepmc   +1 more source

Dupilumab for the treatment of pemphigoid gestationis in the setting of breastfeeding: a case report and review of the literature. [PDF]

Skin Health Dis
Soto-Canetti G, Navrazhina K, Talia J.
europepmc   +1 more source

Increased risk of atrial fibrillation among patients with bullous pemphigoid: a nationwide cohort study in Taiwan. [PDF]

An Bras Dermatol
Chen TL, Huang WT, Wu CY, Loh CH, Huang HK, Ching-Chi C.   +5 more
europepmc   +1 more source

Therapeutic expansion of JAK inhibitors in Chinese dermatological practice: beyond atopic dermatitis to novel autoimmune frontiers. [PDF]

Front Med (Lausanne)
Lyu X, Wang Y, Yang J, Zhang Y, Min W, Du N.   +5 more
europepmc   +1 more source

Anti-p200 Pemphigoid in an Infant Clinically Mimicking Linear IgA Disease. [PDF]

Pediatr Dermatol
Wellman EA, Conlon JD, Leiferman KM, Wilson ML.   +3 more
europepmc   +1 more source

An atypical presentation of Pembrolizumab-induced bullous pemphigoid in a patient with uterine serous carcinoma. [PDF]

Gynecol Oncol Rep
Chen RY, Vasavda C, Imadojemu S, Liu SW, Campos SM.   +4 more
europepmc   +1 more source

Patient Perspectives on Treatment Outcomes and Priorities in Autoimmune Bullous Diseases: An Exploratory Survey among Dutch Patients.

Dermatology
Hiel MAJ, Korte EWH, Bolling MC, Meijer JM, Horváth B.   +4 more
europepmc   +1 more source